Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.
Also called NCT03257410
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 172 participants
- Registry
-
NCT03257410
-
- Other papers using this trial's data
- Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03257410. Randomized; no masking; primary purpose treatment. Start 2017-09-29 (actual); primary completion 2018-10-27 (actual). Results posted on 2020-12-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
- Condition
- End Stage Renal Disease
- Intervention (Device)
- Theranova 400 dialyzer
- Intervention (Device)
- Elisio-17H dialyzer
- Lead sponsor
- Vantive Health LLC
- Collaborator
- Baxter Healthcare Corporation
Record details
- Record id
cardio:ct-nct03257410- Content hash
41d30be64ce0f94a817bc6386da019111b8ab3e8056012069beae0976ec31995